Molecular Partners announced today the appointment of Andreas Emmenegger as Chief Financial Officer and member of the company’s Executive Management Committee.
In his most recent position, Andreas Emmenegger (Switzerland) was Head of Strategic Alliance Finance (Genentech) of F. Hoffmann-La Roche Ltd. In this function, he was mainly in charge of the financial matters in R&D regarding the strategic alliance of Roche and Genentech Inc, San Francisco. Prior to that, he was Chief Financial Officer of GLYCART biotechnology, where he contributed to the successful CHF 235 million company trade sale to the F. Hoffmann-La Roche Group in July 2005. A. Emmenegger has more than 10 years of experience as CFO of several public and private multinational companies, for one of which he performed an IPO raising CHF 120 million. He also has extensive experience with capital markets as well as in M&A and start up fund raising. He holds an Executive MBA degree from IESE Business School, Barcelona.
“We are delighted that Andreas Emmenegger joined our company”, said Christian Zahnd, PhD, CEO of Molecular Partners. “His achievements as well as expertise in financial management of private and listed companies will make a significant contribution to the financial and strategic development of our company. His track record in a biotech start-up as well as in big pharma combined with his entrepreneurial personality is a perfect match with our needs in this dynamic and crucial stage of our corporate development”.